Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cushing's syndrome and bone.

Tatiana Mancini1, Mauro Doga, Gherardo Mazziotti

  • 1Division of Medicine, San Marino Hospital, Republic of San Marino.

Pituitary
|July 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of chronic cholecalciferol supplementation and vitamin D status on risk of post-vaccination SARS-CoV-2 breakthrough infection.

Endocrine·2026
Same author

Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?

Pituitary·2026
Same author

DPP3 deficiency impacts bone quality and sensitizes to metabolic alterations.

Bone·2026
Same author

Current application and future directions for the sarcopenic obesity Global Leadership Initiative (SOGLI) diagnostic algorithm.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Body composition in male hypogonadism: practical considerations to the use of dual-energy x-ray absorptiometry.

Reviews in endocrine & metabolic disorders·2026
Same author

Neuroendocrine and neural control of bone mass in health and disease.

The Journal of clinical investigation·2026
Same journal

Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.

Pituitary·2026
Same journal

Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

Pituitary·2026
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
See all related articles

Cushing's syndrome (CS) causes significant bone loss and fractures, especially in the spine. Bone density recovery is slow, but treatments like alendronate can help prevent further skeletal damage.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Skeletal Health

Background:

  • Cushing's syndrome (CS) frequently leads to skeletal morbidity, including fractures and osteoporosis.
  • Children with CS experience growth impairment, affecting adult height and peak bone mass.
  • Reduced osteoblast function is a key factor in CS-related bone loss.

Purpose of the Study:

  • To summarize the skeletal complications of Cushing's syndrome.
  • To discuss diagnostic and management strategies for bone health in CS patients.
  • To review the reversibility and treatment of glucocorticoid-induced osteoporosis.

Main Methods:

  • Review of literature on skeletal manifestations in Cushing's syndrome.
  • Analysis of bone mineral density (BMD) measurement recommendations.

Related Experiment Videos

  • Discussion of therapeutic interventions for bone loss.

    • Main Results:

    • Osteoporosis affects 50% of CS patients, with spinal fractures common.
    • Decreased serum osteocalcin and alkaline phosphatase levels are observed.
    • Bone mineral density (BMD) measurement via DEXA is recommended, particularly at the lumbar spine.
    • Skeletal follow-up is crucial, even after CS cure, due to persistent damage.
    • Bone loss recovery in CS is slow, taking up to ten years.
    • Alendronate may accelerate BMD improvement and prevent fractures in severe cases.

    Conclusions:

    • Cushing's syndrome poses a significant risk for skeletal impairment and fractures.
    • Regular monitoring and appropriate treatment, including potential use of alendronate, are essential for managing bone health in CS patients.
    • While glucocorticoid-induced osteoporosis is reversible, recovery is prolonged, necessitating long-term management strategies.